

Cancer Immunotherapy-China Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/C95336C2094EN.html

Date: February 2018

Pages: 149

Price: US\$ 2,980.00 (Single User License)

ID: C95336C2094EN

Abstracts

Report Summary

Cancer Immunotherapy-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Immunotherapy industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Cancer Immunotherapy 2013-2017, and development forecast 2018-2023

Main market players of Cancer Immunotherapy in China, with company and product introduction, position in the Cancer Immunotherapy market

Market status and development trend of Cancer Immunotherapy by types and applications

Cost and profit status of Cancer Immunotherapy, and marketing status Market growth drivers and challenges

The report segments the China Cancer Immunotherapy market as:

China Cancer Immunotherapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China Northeast China East China Central & South China



Southwest China

Northwest China

China Cancer Immunotherapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Melanoma

Colorectal cancer

Prostate cancer

Head and neck cancer

Breast cancer

Lung cancer

Other

China Cancer Immunotherapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Others

China Cancer Immunotherapy Market: Players Segment Analysis (Company and Product introduction, Cancer Immunotherapy Sales Volume, Revenue, Price and Gross Margin):

Amgen

AstraZeneca

F. Hoffman La-Roche

Bayer AG

Bristol-Myers Squibb

Eli Lilly and Company

Janssen Global Services

Merck

Novartis

Pfizer

Seattle Genetics

Peregrine Pharmaceuticals

Viralytics Ltd

Immunomedics



In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF CANCER IMMUNOTHERAPY

- 1.1 Definition of Cancer Immunotherapy in This Report
- 1.2 Commercial Types of Cancer Immunotherapy
 - 1.2.1 Melanoma
 - 1.2.2 Colorectal cancer
 - 1.2.3 Prostate cancer
 - 1.2.4 Head and neck cancer
 - 1.2.5 Breast cancer
 - 1.2.6 Lung cancer
 - 1.2.7 Other
- 1.3 Downstream Application of Cancer Immunotherapy
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Cancer Immunotherapy
- 1.5 Market Status and Trend of Cancer Immunotherapy 2013-2023
 - 1.5.1 China Cancer Immunotherapy Market Status and Trend 2013-2023
- 1.5.2 Regional Cancer Immunotherapy Market Status and Trend 2013-2023

CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Cancer Immunotherapy in China 2013-2017
- 2.2 Consumption Market of Cancer Immunotherapy in China by Regions
 - 2.2.1 Consumption Volume of Cancer Immunotherapy in China by Regions
- 2.2.2 Revenue of Cancer Immunotherapy in China by Regions
- 2.3 Market Analysis of Cancer Immunotherapy in China by Regions
 - 2.3.1 Market Analysis of Cancer Immunotherapy in North China 2013-2017
 - 2.3.2 Market Analysis of Cancer Immunotherapy in Northeast China 2013-2017
 - 2.3.3 Market Analysis of Cancer Immunotherapy in East China 2013-2017
 - 2.3.4 Market Analysis of Cancer Immunotherapy in Central & South China 2013-2017
 - 2.3.5 Market Analysis of Cancer Immunotherapy in Southwest China 2013-2017
 - 2.3.6 Market Analysis of Cancer Immunotherapy in Northwest China 2013-2017
- 2.4 Market Development Forecast of Cancer Immunotherapy in China 2018-2023
 - 2.4.1 Market Development Forecast of Cancer Immunotherapy in China 2018-2023
 - 2.4.2 Market Development Forecast of Cancer Immunotherapy by Regions 2018-2023



CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole China Market Status by Types
 - 3.1.1 Consumption Volume of Cancer Immunotherapy in China by Types
 - 3.1.2 Revenue of Cancer Immunotherapy in China by Types
- 3.2 China Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in North China
 - 3.2.2 Market Status by Types in Northeast China
 - 3.2.3 Market Status by Types in East China
 - 3.2.4 Market Status by Types in Central & South China
 - 3.2.5 Market Status by Types in Southwest China
 - 3.2.6 Market Status by Types in Northwest China
- 3.3 Market Forecast of Cancer Immunotherapy in China by Types

CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Cancer Immunotherapy in China by Downstream Industry
- 4.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Cancer Immunotherapy by Downstream Industry in North China
- 4.2.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Northeast China
- 4.2.3 Demand Volume of Cancer Immunotherapy by Downstream Industry in East China
- 4.2.4 Demand Volume of Cancer Immunotherapy by Downstream Industry in Central & South China
- 4.2.5 Demand Volume of Cancer Immunotherapy by Downstream Industry in Southwest China
- 4.2.6 Demand Volume of Cancer Immunotherapy by Downstream Industry in Northwest China
- 4.3 Market Forecast of Cancer Immunotherapy in China by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER IMMUNOTHERAPY

- 5.1 China Economy Situation and Trend Overview
- 5.2 Cancer Immunotherapy Downstream Industry Situation and Trend Overview



CHAPTER 6 CANCER IMMUNOTHERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA

- 6.1 Sales Volume of Cancer Immunotherapy in China by Major Players
- 6.2 Revenue of Cancer Immunotherapy in China by Major Players
- 6.3 Basic Information of Cancer Immunotherapy by Major Players
- 6.3.1 Headquarters Location and Established Time of Cancer Immunotherapy Major Players
- 6.3.2 Employees and Revenue Level of Cancer Immunotherapy Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 CANCER IMMUNOTHERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Amgen
 - 7.1.1 Company profile
 - 7.1.2 Representative Cancer Immunotherapy Product
 - 7.1.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Amgen
- 7.2 AstraZeneca
 - 7.2.1 Company profile
 - 7.2.2 Representative Cancer Immunotherapy Product
 - 7.2.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.3 F. Hoffman La-Roche
 - 7.3.1 Company profile
- 7.3.2 Representative Cancer Immunotherapy Product
- 7.3.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of F. Hoffman La-Roche
- 7.4 Bayer AG
 - 7.4.1 Company profile
 - 7.4.2 Representative Cancer Immunotherapy Product
- 7.4.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.5 Bristol-Myers Squibb
 - 7.5.1 Company profile
 - 7.5.2 Representative Cancer Immunotherapy Product
 - 7.5.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bristol-



Myers Squibb

- 7.6 Eli Lilly and Company
 - 7.6.1 Company profile
 - 7.6.2 Representative Cancer Immunotherapy Product
- 7.6.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
- 7.7 Janssen Global Services
 - 7.7.1 Company profile
 - 7.7.2 Representative Cancer Immunotherapy Product
- 7.7.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Janssen Global Services
- 7.8 Merck
 - 7.8.1 Company profile
- 7.8.2 Representative Cancer Immunotherapy Product
- 7.8.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Merck
- 7.9 Novartis
 - 7.9.1 Company profile
 - 7.9.2 Representative Cancer Immunotherapy Product
 - 7.9.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Novartis
- 7.10 Pfizer
 - 7.10.1 Company profile
 - 7.10.2 Representative Cancer Immunotherapy Product
 - 7.10.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Pfizer
- 7.11 Seattle Genetics
 - 7.11.1 Company profile
 - 7.11.2 Representative Cancer Immunotherapy Product
- 7.11.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Seattle Genetics
- 7.12 Peregrine Pharmaceuticals
 - 7.12.1 Company profile
 - 7.12.2 Representative Cancer Immunotherapy Product
- 7.12.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Peregrine Pharmaceuticals
- 7.13 Viralytics Ltd
 - 7.13.1 Company profile
 - 7.13.2 Representative Cancer Immunotherapy Product
- 7.13.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Viralytics Ltd
- 7.14 Immunomedics



- 7.14.1 Company profile
- 7.14.2 Representative Cancer Immunotherapy Product
- 7.14.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Immunomedics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER IMMUNOTHERAPY

- 8.1 Industry Chain of Cancer Immunotherapy
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER IMMUNOTHERAPY

- 9.1 Cost Structure Analysis of Cancer Immunotherapy
- 9.2 Raw Materials Cost Analysis of Cancer Immunotherapy
- 9.3 Labor Cost Analysis of Cancer Immunotherapy
- 9.4 Manufacturing Expenses Analysis of Cancer Immunotherapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER IMMUNOTHERAPY

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation



- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Cancer Immunotherapy-China Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/C95336C2094EN.html

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C95336C2094EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970